Z
Zenflow
Minimally-invasive approach to treating benign prostatic hyperplasia (BPH) or enlarged prostate
About Zenflow
Zenflow is a medical device company that has developed the Spring® System, a minimally invasive treatment for men suffering from an enlarged prostate, also known as benign prostatic hyperplasia (BPH).
The company's approach is to provide a long-term solution that avoids the side effects and risks associated with medications and more invasive surgical procedures. The Spring® System is designed to be a straightforward, office-based procedure that can be completed in a short amount of time, allowing patients to recover quickly and resume their normal activities.
Zenflow is currently in the process of seeking regulatory approval for its device. The company has completed a pivotal clinical trial, the BREEZE study, and is using the results to support its application to the U.S. Food and Drug Administration (FDA) for pre-market approval. To fund this process and prepare for the commercial launch of the Spring® System, Zenflow has recently secured $24 million in a financing round.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- South San Francisco, United States
- Employees
- 41
- Open positions
- None listed
- Dealroom signal
- 92.1/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Non-Invasive medical devices and treatments, Spinout, Mentech, Biotech and Pharma, YC W15, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Nov 2024 | $24M | $157M | Invus · Cook Medical · F-Prime · MedTech VP | ↗ |
| SERIES BOther financing | Jun 2021 | $24M | $157M | F-Prime · MedTech VP · Astia Angels · Invus | — |
Growth signals
Latest recorded traffic for Zenflow is 1.8K monthly website visits, down 66.7% over the last three months. Zenflow's team grew 28.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Wei Guo
Y Combinator
National Institutes of Health
US National Science Foundation
Series A9 investors entered at this stage
Eight Roads Ventures
Invus
F-Prime
SV Tech Ventures
UpHonest Capital
MedTech VP
ShangBay Capital- AAAstia Angels
- CFCloudstone Venture Fund
Series B and later1 investor entered at this stage
Cook Medical
Other known investors1 additional known investor
Stanford University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zenflow on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zenflow’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.